Novel in situ gelling ocular inserts for voriconazole-loaded niosomes: Design, in vitro characterisation and in vivo evaluation of the ocular irritation and drug pharmacokinetics

Journal of Microencapsulation

Volumn 33, Issue 1, 2016, Pages 71-79

  Shukr, Marwa Hassan ^a  

^a NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

Author keywords

In situ gel; niosomes; ocular insert; voriconazole

Indexed keywords

ALGINIC ACID; CARBOXYMETHYLCELLULOSE; CHOLESTEROL; NIOSOME; POLOXAMER; SORBITAN PALMITATE; SORBITAN STEARATE; SURFACTANT; VORICONAZOLE; GLUCURONIC ACID; HEXURONIC ACID; LIPOSOME; PLURONIC L64;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; EYE IRRITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MUCOADHESION; NANOENCAPSULATION; NONHUMAN; PH; PHOTON CORRELATION SPECTROSCOPY; SURFACE PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; WATER TRANSPORT; ZETA POTENTIAL; ANIMAL; CHEMISTRY; INTRAOCULAR DRUG ADMINISTRATION; MALE; PARTICLE SIZE; RAT;

ALGINATES; ANIMALS; CARBOXYMETHYLCELLULOSE SODIUM; GLUCURONIC ACID; HEXURONIC ACIDS; INJECTIONS, INTRAOCULAR; LIPOSOMES; MALE; PARTICLE SIZE; POLOXAMER; RATS; VORICONAZOLE;

EID: 84959478994     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2015.1128489     Document Type: Article

References (58)

1. Abdelbary G, El-gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech, 2008; 9: 740-7.
2. Abdelbary A, El-laithy HM, Tadros MI. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm, 2008; 357: 189-98.
3. Abdelkader H, Wu Z, Al-Kassas R, Brown JE, Alany RG. Preformulation characteristics of the opioid growth factor antagonist-naltrexone hydrochloride: Stability and lipophilicity studies. J Drug Del Sci Technol, 2011a; 21: 157-63.
4. Abdelkader H, Patel DV, Mc Ghee CN, Alany RG. New therapeutic approaches in the treatment of diabetic keratopathy: A review. Clin Exp Ophthalmol, 2011b; 39: 259-70.
5. Abdelkader H, Alani AW, Alany RG. Recent advances in nonionic surfactant vesicles (niosomes): Self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv, 2013; 21: 87.
6. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm, 2005; 290: 155-9.
7. Ahmed IS, Aboul-Einien MH. In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin. Eur J Pharm Sci, 2007; 32: 58-68.
8. Aripin NFK, Park JW, Park HJ. Preparation of vesicle drug carrier from palm oil-and palm kernel oil-based glycosides. Colloids Surf B, Biointerfaces, 2012; 95: 144-53.
9. Balakrishnan P, Shanmugam S, Lee WS, Lee WM, Kim JO, Oh DH, Kim DD, Kim JS, Yoo BK, Choi HG, et al. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm, 2009; 377 (1-2): 1-8.
10. Basaran E, Demirel M, Sirmagul B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul, 2010; 27: 37-47.
11. Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci, 2010; 99: 2049-60.
12. Bernsdorff C, Wolf A, Winter R, Gratton E. Effect of hydrostatic pressure on water penetration and rotational dynamics in phospholipid-cholesterol bilayers. Biophys J, 1997; 72 (3): 1264-77.
13. Bertram U, Bernard MC, Haensler J, Maincent P, Bodmeier R. In situ gelling nasal inserts for influenza vaccine delivery. Drug Dev Ind Pharm, 2010; 36: 581-93.
14. Bertram U, Bodmeier R. Effect of polymer molecular weight and of polymer blends on the properties of rapidly gelling nasal inserts. Drug Dev Ind Pharm, 2012; 38 (6): 659-69.
15. Bertram U, Bodmeier R. In situ gelling, bioadhesive nasal inserts for extended drug delivery: In vitro characterization of a new nasal dosage form. Eur J Pharm Sci, 2006; 27: 62-71.
16. Bhatta RS, Chandasana H, Chhonker YS, Rathi C, Kumar D, Mitra K, Shukla PK. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. Int J Pharm, 2012; 432: 105-12.
17. Colo DG, Burgalassi S, Chetoni P, Fiaschi MP, Zambito Y, Saettone MF. Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Int J Pharm, 2001; 215: 101-11.
18. Dai YK, Zhou R, Liu L, Lu Y, Qi JP, Wu W. Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): In vitro characterization and improved corneal permeation. Int J Nanomed, 2013; 8: 1921-33.
19. Deasy PBO, Neill CT. Bioadhesive dosage form for peroral administration of timolol base. Pharm Acta Helv, 1989; 64: 231.
20. deSá FA, Taveira SF, Gelfuso GM, Lima Em Gratieri T. Liposomal voriconazole (VOR) formulation for improved ocular delivery. Colloids Surf B Biointerfaces, 2015; 133: 331-8.
21. El-Laithy HM, Nesseem DI, El-Adly AA, Shoukry M. Moxifloxacin-Gelrite in situ ophthalmic gelling system against photodynamic therapy for treatment of bacterial corneal inflammation. Arch Pharm Res, 2011; 34: 1663-78.
22. Farid RM, Etman MA, Nada AH, Ebian AA. Formulation and in vitro evaluation of salbutamol sulphate in situ gelling nasal inserts. AAPS Pharm SciTech, 2013; 14: 712-18.
23. Giddi H, Arunagirinathan M, Bellare J. Self-assembled surfactant nano-structures important in drug delivery: A review. Indian J Exp Biol, 2007; 45 (2): 133-59.
24. Gilhotra RM, Gilhotra N, Mishra DN. Piroxicam bioadhesive ocular inserts: Physicochemical characterization and evaluation in prostaglandin-induced inflammation. Curr Eye Res, 2009; 34: 1065-73.
25. Gratieri T, Gelfuso GM, de Freitas O, Rocha EM, Lopez RF. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. Eur J Pharm Biopharm, 2011; 79: 320-7.
26. Gregoriadis G, Davis C. Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells. Biochem Biophys Res Commun, 1979; 89 (4): 1287-93.
27. Gupta S, Shrivastava RM, Tandon R, Gogia V, Agarwal PD, Satpathy G. Role of voriconazole in combined acanthamoeba and fungal corneal ulcer. Cont Lens Anterior Eye, 2011; 34: 287-9.
28. Hosny KM. Ciprofloxacin as ocular liposomal hydrogel. AAPSPharmSciTech, 2010; 11: 241-6.
29. Kapoor Y, Chauhan A. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int J Pharm, 2008; 361: 222-9.
30. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release, 2008; 127: 97-109.
31. Kaur IP, Kakkar S. Topical delivery of antifungal agents. Expert Opin Drug Deliv, 2010; 7: 1303-27.
32. Kaur IP, Rana C, Singh M, Bhushan S, Singh H, Kakkar S. Development and evaluation of novel surfactant-based elastic vesicular system for ocular delivery of fluconazole. J Ocul Pharmacol Ther, 2012; 28 (5): 484-96.
33. Khoschsorur GA, Fruehwirth F, Zelzer S. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob Agents Chemother, 2005; 49 (8): 3569-71.
34. Khutoryanskaya OV, Morrison PW, Seilkhanov SK, Mussin MN, Ozhmukhametova EK, Rakhypbekov TK, Khutoryanskiy VV. Hydrogen-bonded complexes and blends of poly(acrylic acid) and methylcellulose: Nanoparticles and mucoadhesive films for ocular delivery of riboflavin. Macromol Biosci, 2014; 14: 225-34.
35. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J, 1980; 186 (2): 591-8.
36. Kumarn G, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery-An overview. Acta Pharm Sin B, 2011; 1 (4): 208-19.
37. Lat A, Thompson GR. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist, 2011; 4: 43-53.
38. Liang QF, Jin XY, Wang XL, Sun XG. Effect of topical application of terbinafine on fungal keratitis. Chin Med J, 2009; 122: 1884-8.
39. Luschmann C, Tessmar J, Schoeberl S, Strauss O, Framme C, Luschmann K, Goepferich A. Developing an in situ nanosuspension: A novel approach towards the efficient administration of poorly soluble drugs at the anterior eye. Eur J Pharm Sci, 2013; 50: 385-92.
40. Mansour M, Mansour S, Mortada ND, Abd Elhady SS. Ocular poloxamer based ciprofloxacin hydrochloride in situ forming gels. Drug Dev Ind Pharm, 2008; 34: 744-52.
41. Masotti A, Vicennati P, Alisi A. NovelTween 20 derivatives enable the formation of efficient pH-sensitive drug delivery vehicles for human hepatoblastoma. Bioorg Med Chem Lett, 2010; 20 (10): 3021-5.
42. Mishra DN, Gilhotra RM. Design and characterization of bioadhesive in-situ gelling ocular inserts of gatifloxacin sesquihydrate. Daru, 2008; 16: 1-8.
43. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm, 2001; 229: 29-36.
44. Nafee NA, Ismail FA, Boraie NA, Mortada LM. Mucoadhesive buccal patches of miconazole nitrate: In vitro/in vivo performance and effect of ageing. Int J Pharm, 2003; 264: 1-14.
45. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm, 2007; 328 (2): 130-41.
46. Parthasarathi G, Udupa N, Umadevi P, Pillai GK. Niosome encapsulated of vincristine sulfate: Improved anticancer activity with reduced toxicity in mice. J Drug Target, 1994; 2: 173-82.
47. Paulsson M, Hagerstrom H, Edsman K. Rheological studies of the gelation of deacetylated gellan gum (GelriteR) in physiological conditions. Eur J Pharm Sci, 1999; 9: 99-105.
48. Rodriguez CF, Bruneau N, Barra J, Alfonso D, Doelker E. 2000. Hydrophilic cellulose derivatives as drug delivery carriers: Influence of the substitution type on the properties of compressed matrix tablets. In: Wise DL., ed. Handbook of pharmaceutical controlled release technology. New York: Marcell Dekker, pp. 1-30.
49. Shahiwala A, Misra A. Studies in topical application of niosomally entrapped Nimesulide. J Pharm Pharmaceut Sci: A Publ Can Soc Pharmaceut Sci Soc Can Sci Pharmaceut, 2002; 5 (3): 220-5.
50. Shen J, Deng Y, Jin X, Ping Q, Su Z, Li L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Int J Pharm, 2010; 402: 248-53.
51. Singh M, Tiwary AK, Kaur G. Investigations on interpolymer complexes of cationic guar gum and xanthan gum for formulation of bioadhesive films. Res Pharm Sci, 2010; 5: 79-87.
52. Skjak-Brak G. Alginates: Biosyntheses and some structure-function relationships relevant to biomedical and biotechnological applications. Biochem Soc Trans, 1992; 20: 27-33.
53. Tamilvanana S, Benitab S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm, 2004; 58: 357-68.
54. Tavano L, Vivacqua M, Carito V, Muzzalupo R, Caroleo MC, Nicoletta F. Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloids Surf B Biointerfaces, 2013; 102: 803-7.
55. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm, 1998; 172: 33-70.
56. Wang PY, Bazos MJ. 1983. Polymer surface interactions in the biological environment. In: Mittal KL., ed. Physicochemical aspects of polymer surfaces. New York: Plenum Press, pp. 143-98.
57. Werner U. 2003. In situ gelling nasal inserts for prolonged drug delivery. Berlin: Fachbereich Biologie, Chemie, Pharmazieder Freien Universitat Berlin.
58. Wiebe V, Karriker M. Therapy of systemic fungal infections: A pharmacologic perspective. Clin Tech Small Anim Pract, 2005; 20: 250-7.